Chronic pelvic pain in women: an epidemiological perspective by Ayorinde, Abimbola A. et al.
851Womens Health (2015) 11(6), 851–864 ISSN 1745-5057
part of
Review
10.2217/whe.15.30 © 2015 Future Medicine Ltd
Womens Health
Review 2015/08/30
11
6
864
2015
Chronic pelvic pain (CPP) is common in women of reproductive age and has a 
significant impact on quality of life, work efficiency and healthcare utilization. CPP 
can be a manifestation of many different, often multifactorial conditions, and in the 
absence of an identified cause, the management can be particularly challenging. High 
quality epidemiological studies would improve the understanding of CPP and identify 
risk factors which may be targeted for the development of appropriate management 
strategies. This review focuses on what is known about the prevalence, risk factors, 
individual and societal burden of CPP and outlines important management strategies.
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Chronic pelvic pain (CPP) in women can be 
an incapacitating condition with a significant 
impact on health-related quality of life, work 
efficiency and healthcare utilization [1–4]. 
Nevertheless, CPP is frequently neglected by 
healthcare professionals due to lack of clear 
understanding of the condition and paucity 
of good quality epidemiological data [4,5]. 
The etiology of CPP, which involves a com-
plex interplay of physical and psychological 
factors, is not fully understood and there is 
no standardized approach to its definition, 
evaluation and treatment [6]. While CPP 
could be a symptom of an underlying pathol-
ogy of various organ systems, it can be argued 
that it is a syndrome in its own right [7]. This 
review describes the current epidemiologi-
cal knowledge of CPP in women, highlights 
areas for further research and also outlines 
current management strategies.
Definition
Sound epidemiological research requires an 
explicit and consistent definition of the health 
problem being studied. The heterogeneity of 
the definitions used for CPP introduced chal-
lenges for comparing results across different 
studies [8]. Some definitions include a mea-
sure of severity of symptoms. The American 
Congress of Obstetricians and Gynecologists 
defines CPP as noncyclical pain in the pelvis, 
severe enough to require medical attention, 
located below the umbilicus in the region 
of the anterior abdominal wall, lumbosa-
cral back or buttocks lasting for at least 6 
months [9]. The value of such definitions in 
epidemiological studies remains debatable, 
particularly when severity is measured by dis-
ability or need for medical attention. Psycho-
logical, social and demographic factors could 
also influence disability and treatment seek-
ing behavior [10–12]. Most population-based 
epidemiological studies have defined CPP 
as “cyclical or noncyclical lower abdominal 
pain of at least 6 months duration, which is 
unrelated to pregnancy and not exclusively 
due to dysmenorrhea or dyspareunia” (see 
Table 1). This definition is consistent with 
the one adopted by the Royal College of 
Obstetricians and Gynecologists (RCOG), 
and is used in this review [13].
Prevalence
A number of studies have reported the prev-
alence of CPP in women but most of them 
have used sampling frames such as hospital 
patients which are unable to provide accurate 
estimates of the prevalence of CPP in the gen-
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eral population [20–25]. The relatively few population-
based studies have reported prevalence ranging from 
6.4% in Mexico [16] to 25.4% in New Zealand [3] (see 
Table 1). The studies were conducted using randomly 
selected women from representative sampling frames 
with sample sizes ranging from 1160 [3] to 5263 [1]. It 
is worth noting that differences in study designs, case 
definitions and survey methods may have contributed 
significantly to the variation in reported prevalence 
rates across different countries.
The earliest population survey for CPP, conducted in 
the USA in 1994 found a prevalence of 14.7% [1]. Stud-
ies from the UK, New Zealand and Australia reported 
prevalence of 24, 25.4 and 21.5%, respectively [2–3,15]. 
The prevalence rates in the last three studies were higher 
than that reported in the first study, possibly because 
women with mid-cycle pain were excluded from the 
USA study. Exclusion of women with mid-cycle pain 
from the UK and New Zealand studies reduced the 
prevalence rates to 16.9 and 16.5%, respectively. Mexi-
can data obtained in 2005 based on face-to-face inter-
views of relatively older (25–54 years) women showed 
a 12-month period prevalence of 6.4% [16], which is the 
lowest prevalence rate identified, despite the use of a 
similar definition of CPP as the previous studies.
All the aforementioned studies were conducted 
among women of reproductive age. Older women who 
are believed to be less susceptible to CPP have been tra-
ditionally excluded from prevalence studies. In 1994, 
a cross-sectional analysis of a primary care database 
in the UK found higher rates of CPP in women aged 
61–73 compared with women in younger age groups 
(monthly prevalence of approximately 27/1000 vs 
21/1000) [26]. More recent population studies have also 
confirmed significant reporting of CPP among older 
women [17–19]. While the highest rate reported in one 
of the studies was in women aged 18–25 years (17%), 
women older than 75 years had a rate of 13% [19].
Individual & societal burden
CPP has a considerable impact on the well-being of 
women and is a cause of significant distress and dis-
ability [27]. It has been reported to be associated with 
poor quality of life, fatigue, depression, anxiety, mari-
tal and sexual dysfunction [1–3,14,28–29]. Loss of work-
ing days and diminished work capacity were reported 
by 15 and 45% of affected women, respectively, in 
a study from the USA [1]. Patients with CPP tended 
to spend days in bed due to illness and report poorer 
physical and mental health compared with the general 
population [30]. In the absence of a specific diagnosis, 
women often experience despair, lose personal confi-
dence, become increasingly isolated and may even be 
suicidal [31].
Influences of psychological factors on the experi-
ence of pain are also important. Generally, quality of 
life in chronic pain has been shown to be considerably 
associated with beliefs about pain than the pain inten-
sity [32]. A prospective study of 115 women with endo-
metriosis-associated CPP showed that catastrophizing 
(i.e., negative cognitive and emotional coping response 
including amplification of pain and feeling of help-
lessness) had a significant impact on the experience of 
pain [33]. A cross-sectional study showed that a diagno-
sis of endometriosis did not influence quality of life or 
anxiety-depression symptoms in women with CPP but 
higher pain intensity was associated with lower qual-
ity of life [34]. Similarly, post-traumatic stress disorder 
has been found to be related to poor health status in 
women with CPP [35].
The majority of women with CPP do not seek medi-
cal advice. A study in the UK in 2001 showed that only 
32% of women with CPP had sought medical advice 
in the past year (recent consulters), 41% had never 
done so (nonconsulters) while about 27% had sought 
medical help early, but not within the past year (past 
consulters) [36]. This study also found that while recent 
consulters had more severe symptoms, all were affected 
by their pain and many, including nonconsulters, 
remained anxious about the cause of their pain. Forty-
three per cent of past consulters reported that their 
activities were restricted by their pain. It is not clear why 
women do not seek medical help or discontinue contact 
with their healthcare providers despite the persistence 
of their symptoms. The authors suggested that the rea-
son for this could either be because women continue 
to favor self-medication or because they are dissatisfied 
with the treatment provided [36]. These suggestions are 
supported in other studies. A study showed that 58.4% 
of women with CPP reported that they use analgesics 
and/or nonsteroidal anti-inflammatory drugs on a 
weekly or daily basis without medical  prescription [18].
Furthermore, a focus group study involving a total 
of 36 women in New Zealand reported that many of 
the women seeking medical input from General Prac-
titioners and/or gynecologists experienced problems 
with their consultations [37]. These problems include 
difficulties with communication with the healthcare 
provider, diagnosis, diagnostic procedure, referral, 
medication and surgery. Another study also reported 
problems with the doctor–patient relationship mainly 
due to communication problems which led to women 
feeling devalued and dejected and unwilling to re-
engage with the consultation process despite the per-
sistence of their pain [38]. The studies highlighted the 
need for healthcare providers to develop communica-
tion strategies, so that the patients do not feel that their 
symptoms are dismissed. Improved communication 
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Figure 1. Examples of conditions that may be associated with chronic pelvic pain in women.
• Irritable bowel syndrome
• Inflammatory bowel disease
• Constipation
• Herniae
• • Chronic coccygeal pain
••• Compression of lumber vertebrae
• • Spondylosis
• • Faulty or poor posture
• • Pelvic floor myalgia
• • Hip dysfunction/arthritis
• • Labrum tears
• • Fibromyalgia
• Endometriosis
• Adhesions
• Pelvic congestion syndrome
• Ovarian remnant syndrome
• Chronic pelvic inflammatory disease
• Cervical stenosis
• Adenomyosis
• Atypical dysmenorhoea or ovulatory pain
• Interstitial cystitis
• Bladder neoplasm
• Stone/urolithiasis
• Chronic urinary tract infection
• Neuropathic pain
• Nerve entrapment
• Complex regional pain syndrome
• Physical and sexual abuse
• Depression
• Anxiety
• Somatoform disorders
• Post-traumatic stress disorder
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skills are also fundamental for providing the patient 
with sufficient information about diagnosis and treat-
ment options to ensure that the patients are involved in 
making informed decisions and are considered as equal 
partners in their care. A study of primary care practi-
tioners’ perspectives showed a lack of awareness of how 
the condition should be diagnosed and treated which 
also threatens the practitioners’ perceptions of their 
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own clinical competencies [39]. Additional education 
and training is needed for primary care practitioners to 
effectively prepare them in helping women with CPP.
CPP accounts for about 40% of gynecological lapa-
roscopies, making it the most frequent indication for 
referral to women’s health services [40]. Unsurprisingly, 
it has major financial implications. In the UK, care 
for women with pelvic pain was estimated to cost the 
National Health Service (NHS) more than £158 mil-
lion in 1992 [41]. The equivalent cost today is estimated 
at approximately £326 million based on the inflation 
indices from the hospital and community services 
index [42]. In the USA, the total annual direct cost for 
physician visits and out-of-pocket cost was estimated 
to be USD$2.8 billion in 1996 [1]. This is equivalent 
to USD$5.68 billion today according to the figures in 
the medical care component of the Consumer Price 
Index [43]. A study found that loss of work productivity 
in endometriosis was majorly driven by pelvic pain and 
disease severity [44]. This work productivity loss trans-
lated into substantial cost per woman per week ranging 
from USD$4 in Nigeria to USD$456 in Italy [44].
Etiology & risk factors
Prospective cohort studies which allow exploration of 
the temporal relationship between a risk factor and a 
disease are ideal for identifying factors responsible for 
CPP. As such studies are expensive and time consum-
ing, the majority of the risk factors for CPP reported 
in the literature are derived from cross-sectional stud-
ies. Due to variations in health seeking behavior and 
referral patterns, risk factors identified from primary or 
secondary/tertiary care settings may differ from those 
identified in the community setting [45].
Underlying etiology of CPP has been described in 
various literatures [27,46–48]. CPP can be a manifesta-
tion of urological, gastrointestinal, musculoskeletal, 
gynecological, neurological and psychosocial condi-
tions with often more than one contributory factor and 
a range of diverse risk factors (Figure 1). Sometimes 
the pain is believed to be caused by a single condition 
but often it may be due to a combination of differ-
ent disorders which may have overlapping symptoms 
making it difficult to identify a specific cause in many 
cases. Causes identified are often conditions related to 
the gastrointestinal, gynecological and urological sys-
tems including irritable bowel syndrome (IBS), ovar-
ian cyst, endometriosis and cystitis among others. For 
example, a community-based study in the UK reported 
that only 50% of women received a diagnosis from a 
clinician [36]. The most common diagnoses reported 
were IBS (19.8%), followed by stress (9.5%), ovarian 
cyst (8.4%), endometriosis (7.4%), cystitis (7.2%), 
pelvic inflammatory disease (PID) (6.5%), constipa-
tion (6.5%), back pain (5.7%), uterine fibroid (5.1%), 
adhesions (4.6%), appendicitis (2.5%), inflammatory 
bowel disease (2.1%) and others (12.2%). Similar 
findings were also reported from a study conducted in 
New Zealand [3].
Traditionally, clinicians often sought to identify a 
visceral origin of CPP while musculoskeletal sources 
were frequently overlooked [49]. In a cross-sectional 
study, abnormal pelvic musculoskeletal findings were 
significantly more common among women with CPP 
compared with healthy women [50]. These musculo-
skeletal findings included higher pelvic floor tender-
ness scores (3/24 vs 0/24), poor control of pelvic floor 
(78 vs 20%), pelvic girdle instability (asymmetric 
iliac crest [61 vs 25%], pubic symphysis heights [50 vs 
10%], positive posterior pelvic provocation testing [37 
vs 5%]) [50]. Another study found that when compared 
with healthy controls, women with CPP had more pos-
tural changes in the cervical spine (odds ratio [OR]: 
4.1; 95% CI: 1.6–10.7) and the scapulae (OR: 2.9; 
95% CI: 1.1–7.6) [51]. Thus, musculoskeletal condi-
tions among women with CPP are common and need 
to be more recognized.
CPP may also be neuropathic (pain resulting from 
nerve damage) or of mixed origin. Neuropathic pain 
has been defined by the Special Interest Group on 
Neuropathic Pain of the International Association for 
the Study of Pain as “pain arising as a direct conse-
quence of a lesion or disease affecting the somatosen-
sory system” [52]. This suggests that neuropathic pain 
can originate from a lesion of either the peripheral or 
the CNS [53]. Neurological pain may be a result of a 
wider neurological disorder or secondary to nerve 
entrapment in scar tissue or fascia following surgery 
resulting in pain along the distribution of nerve [54]. 
CPP, like many other chronic pain conditions, involves 
significant changes in the CNS [55,56]. Such changes 
may lead to hyperalgesia (heightened awareness of 
pain) or allodynia (pain in response to stimuli that does 
not normally provoke pain) [56]. Evidence supporting 
neuropathic features (including symptoms like burn-
ing, tingling and pins and needles) in some CPP cases 
is increasing. In a study using the Self-Administered 
Leeds Assessment of Neuropathic Symptoms and Signs 
(S-LANSS) as a screening tool, 31% incidence of neu-
ropathic pain was reported among a sample of 142 CPP 
patients (both men and women) visiting two tertiary 
referral centers [57]. Poorer quality of life was reported 
by those with neuropathic pain symptoms compared 
with those without. Unfortunately, outcomes relat-
ing to women with CPP were not reported separately. 
Higher pain intensity, rates of co-morbid conditions 
and impact on daily life have been reported among 
participants who have chronic pain with neuropathic 
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features compared with those with non-neuropathic 
features [58,59]. These highlight the importance of con-
sidering chronic pain with neuropathic symptoms and 
those without neuropathic symptoms separately.
Psychological factors are also important risk factors 
for CPP. A meta-analysis revealed that the majority of 
the strong correlates identified were within the abuse/
psychological factors domain (particularly psycho-
somatic symptoms, depression, anxiety, physical and 
sexual abuse) when compared with obstetric, gyneco-
logical, environmental and demographic factors [60]. 
Other risk factors for CPP include previous caesarean 
section and previous pelvic trauma [19,61]. A significant 
overlap between CPP, dysmenorrhea and dyspareunia 
has been reported in various population-based stud-
ies. For instance, about 80% of women with CPP also 
reported dysmenorrhea and/or dyspareunia in the UK, 
New Zealand and Australian studies [2–3,15]. A study 
reported that those who report CPP were about four-
times more likely to also report dyspareunia and about 
two-times more likely to report dysmenorrhea [18].
There is no clear pattern of association of CPP with 
socio-demographic factors. A lower risk was reported 
in non-Caucasian women compared with Caucasian 
women in the UK (OR: 0.4; 95% CI: 0.2–0.8) and 
USA (OR: 0.7; 95% CI: 0.5–0.95) [1,2]. The prevalence 
of CPP has been reported to vary across age groups, 
although the patterns were inconsistent [1–3,15]. Com-
pared to single women, women who were divorced, 
separated or widowed were more likely to report CPP in 
one population-based study (OR: 1.51; 95% CI: 1.12–
2.04) [1] but not in some others [2–3,16]. In New Zea-
land, CPP was more common in women with higher 
qualifications (33.0%) than in women with school 
qualifications (21.5%) or no qualifications (23.2%) (p 
= 0.02) [3]. However, CPP was associated with low edu-
cational level in another study in Brazil [17]. There was 
no significant association found between education 
level and the risk of reporting CPP in some other stud-
ies [1,15,18]. CPP was also not significantly  associated 
with employment status or social class [2,3,18].
Diagnosis & management
An in-depth description of diagnosis and management 
strategies for CPP is beyond the scope of this review. 
Current approach to initial assessment and management 
of CPP is discussed below.
As mentioned earlier, some of the conditions mani-
festing as CPP have overlapping symptoms, thus initi-
ating appropriate investigations to identify the cause 
of CPP can be challenging. The diffuse nature of pain 
can make it difficult to localize its origin, adding to the 
complexity of diagnosis [62]. Laparoscopy is unable to 
identify an obvious cause for pain in about half of all 
women with CPP [63]. An initial history and clinical 
examination can help to select appropriate strategies 
for investigation, initiation of treatment or referral to 
an appropriate specialty. Professional bodies represent-
ing various clinical specialties have published guide-
lines on the management of CPP [9,13,64–66]. A mul-
tidisciplinary approach is frequently recommended, 
where a team of specialists including physiotherapists, 
psychologists, gynecologists and pain physicians are 
involved in the care of the patient. It is vital that a 
single clinician orchestrates the multidisciplinary team 
to streamline and individualize care. This minimizes 
the risk of women being seen and given potentially 
 conflicting advice from multiple specialists.
The high disease burden, wide variations in care and 
uncertainty regarding the evidence base underpinning 
some of the interventions have led to the development 
of an integrated care pathway by the Map of Medicine 
and British Pain Society (BPS) [6,66]. The BPS path-
way and the RCOG provide comprehensive guidance 
that focuses on a holistic approach (i.e., management 
which takes into account the biological, psychologi-
cal and social aspects of the person) with initiation of 
treatment in primary care and timelines for onward 
referral to secondary and tertiary care. The BPS path-
way has divided CPP into two distinct entities; CPP 
where an organic cause can be attributed needs to be 
distinguished from CPP syndrome where no obvious 
pathology is identified. CPP syndrome may exist as a 
part of a multisystem disorder with complex interac-
tions of psychosocial, behavioral and sexual factors. A 
caveat with CPP is that pelvic pathology may co-exist 
with CPP syndrome. At the initial visit, an in-depth 
history of physical, social, psychological, sexual factors 
and fertility desires should be sought accompanied by 
general physical and pelvic examination. The identi-
fication of any ‘red flag’ symptoms such as postcoital 
or postmenopausal bleeding, bleeding in stools, large 
pelvic mass, hematuria or signs of major depressive 
disorder should prompt urgent referral to secondary 
care to exclude any sinister pathology [66]. Appropriate 
investigations should then be instituted to confirm or 
refute these clinical findings.
Common gynecological pathologies which can 
present with CPP include endometriosis, adenomyosis, 
ovarian cysts and also sexually transmitted infections. 
Noninvasive investigations such as pelvic swabs, ultra-
sound or magnetic resonance imaging can identify 
sexually transmitted infections (such as uncomplicated 
lower genital tract chlamydia and gonorrhea), PID, 
ovarian cysts and adenomyosis. In women who do not 
wish to conceive, empirical treatment with hormonal 
preparations can be commenced in primary or second-
ary care before embarking on laparoscopy to exclude 
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endometriosis. Previously considered to be a gold stan-
dard in evaluating CPP, laparoscopy is now seen more 
as a second line intervention when other therapeutic 
measures fail [13]. Endometriosis may be treated lapa-
roscopically by excision or ablation. It is a condition 
prone to recurrence and often medical hormonal sup-
pressive treatment is prescribed to reduce the risk of 
recurrence. Any endometriotic or nonendometriotic 
ovarian cysts can be treated during laparoscopy by 
cystectomy or oophorectomy depending on the age 
of the woman, nature of the cyst and future fertility 
intentions. Laparoscopy also permits identification 
and division of adhesions and drainage of tubo-ovar-
ian abscesses that may occur secondary to PID. Pelvic 
pain may be the long term sequela of PID. Hence, a 
low threshold for empirical treatment of PID is recom-
mended using broad spectrum antibiotics [67]. Dyspa-
reunia as a symptom is more complex. Previous sexual 
experiences, abuse, termination of pregnancy and 
other psychosocial factors can have a disproportionate 
influence on the experience of dyspareunia especially 
when associated with vaginismus. These factors should 
be explored during initial assessment and role of psy-
chosexual counseling considered in selected cases.
Gastrointestinal conditions like inflammatory 
bowel disease or IBS may cause or contribute to the 
pelvic pain symptom complex. IBS is a chronic func-
tional bowel disorder characterized by abdominal pain 
or discomfort and associated with bowel dysfunc-
tion. It can be reliably diagnosed using the Rome III 
criteria [68,69]. An improvement in symptoms can be 
achieved by a combination of dietary modifications 
and  pharmacological therapy.
With bladder pain syndrome or interstitial cystitis, 
there is an increased association with other coexisting 
conditions like IBS, fibromyalgia and chronic fatigue 
syndrome [70,71]. The history may point toward lower 
urinary tract symptoms of pain, pressure or discomfort 
associated with urinary frequency, urgency and pain 
that improves after voiding. Cystoscopy and/or biopsy 
may be required in selected cases. Cystoscopy can be 
combined with laparoscopy as interstitial cystitis and 
endometriosis are often considered as the ‘evil twins’ 
of CPP in women [72]. Interstitial cystitis/bladder pain 
syndrome is difficult to treat. The American Urologi-
cal Association recently published updated guidance 
for management ranging from first line to sixth line 
treatments [73]. A multimodal management strategy 
using pharmacological, manual therapy and stress 
management is advocated. Pharmacological treatments 
include use of amitryptiline, cimetidine, hydroxyzine 
or pentosan polysulphate orally. Alternatively, intra-
vesical instillation of various agents, cystoscopy and 
cystodistension may be considered.
Pain of musculoskeletal origin arising from pel-
vic joints or pelvic floor muscles could be attributed 
to CPP. Pelvic examination should include palpation 
of pelvic floor muscles for any trigger points or ten-
der areas. It is unclear whether these musculoskeletal 
anomalies are the primary cause of pain or second-
ary phenomenon elicited by poor posture associated 
with CPP [13,73]. Levator ani spasms, ilio-psoas com-
plex pain and pain arising from piriformis or obtura-
tor muscles may present as pelvic pressure, midvaginal 
dyspareunia, pain shooting down the leg or groin pain. 
The mainstay of treatment for musculoskeletal pelvic 
pain is physiotherapy by trained professionals. Muscle 
relaxants and botulin may sometimes be used [47].
Some women, especially those who have undergone 
multiple pelvic surgeries but still continue to have pain, 
may be experiencing neuropathic pain [54]. Recognizing 
patients with CPP whose symptoms are suggestive of 
neuropathic components could help healthcare provid-
ers plan the most suitable management strategy and pre-
vent inappropriate surgery. Diagnosis and management 
of various peripheral neuropathies that may cause CPP 
have been previously described [54]. Assessment tools are 
available to distinguish whether pain is nociceptive or of 
a possible neuropathic origin [74–78]. Neuromodulating 
agents such as tricyclic antidepressants or anticonvulsants 
are often used for treating the neuropathic component of 
the CPP [57]. Initial reports on the use of gabapentin for 
CPP are promising [79]. Further studies to evaluate the 
use of gabapentin for CPP are underway [80].
Psychological disorders like anxiety, depression and 
sleep disorders are common in women with chronic 
pain conditions but it is difficult to ascertain whether 
these are a consequence of, or contributory to, the 
experience of pain. Sexual issues associated with CPP 
can have a debilitating effect on relationships and 
self-esteem. As a part of multidisciplinary team, pain 
psychologists and psychosexual counselors can help 
address the influence of these factors on perception of 
pain and quality of life.
This review emphasizes the need to acknowledge the 
multifactorial nature of CPP. The diagnosis of ‘CPP 
syndrome’ should be reserved for women in whom a 
thorough evaluation has been performed to exclude 
any treatable pathology. Referral to regional pain man-
agement centers and pain management programs may 
be required for refractory cases. Pain management pro-
grams comprise methods to promote behavior change 
and consequent well-being by educating women on 
pain physiology, pain psychology, general health and 
self-management of pain [81]. Complex cases warrant 
an individual case management approach with inter-
disciplinary and multispecialty assessment. The entire 
concept of CPP management reflects a shift in para-
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digm. There is a move from assigning causality to rec-
ognizing CPP in its totality with management focusing 
on multidisciplinary input, educating and empowering 
women and working in partnership with them.
Conclusion
CPP is a disabling condition, often without an obvi-
ous identifiable cause. This poses a major challenge 
for patients, clinicians and researchers. Clinicians 
often approach CPP from the perspective of their own 
specialty but it is best managed through a holistic 
multidisciplinary approach working closely in part-
nership with women. The epidemiological character-
istics of CPP need to be further established to enable 
in-depth understanding of the burden of CPP in the 
general population and individuals. This requires 
accurate ascertainment of the prevalence of CPP and 
associated risk factors. Understanding the factors that 
influence how women are affected by CPP is an essen-
tial step toward developing and evaluating effective 
 management strategies.
Future perspective
Our understanding of CPP will improve as the syn-
drome continues to attract more research interest. Epide-
miological studies, which have traditionally focused on 
women of childbearing age, are increasingly including 
older women. This is likely to improve our understand-
ing of the etiology of CPP – especially factors such as 
hernias, spondylosis, constipation and pelvic floor dys-
function, which are common at older age. This will also 
aid comparison of CPP studies with other chronic pain 
conditions to help us appreciate the similarities between 
CPP and other regional pain syndromes because epi-
demiological studies of other regional pain syndromes 
have shown strong similarities in etiology, irrespective 
of the site of pain. Prospective studies are important 
for identifying etiology but in order to recruit subjects 
prior to onset of CPP they need to be recruited at young 
ages and long-term follow-up is required. Newer epide-
miological study designs, such as case-crossover studies, 
particularly focused on studying episodes of pain rather 
than first onset, may be more feasible.
While CPP, like other chronic illnesses, may cause 
anxiety and depression, a number of studies have sug-
gested that such psychosocial factors can actually pre-
dict the onset of various pain symptoms [82–88]. Pro-
spective studies are needed to help determine temporal 
relationships between these factors and CPP. Prospec-
tive data would also help to improve the understanding 
of the natural history of CPP in women especially in 
cases where no known cause is identified.
To our knowledge, no population-based study has 
aimed to identify women who have CPP with neuro-
pathic pain features, and consequently the true preva-
lence of neuropathic symptoms among women with 
Executive summary
Definition of chronic pelvic pain (CPP)
•	 Definitions of CPP are mostly based on the duration and localization of pain.
•	 Most frequent definition used in research is “cyclical or noncyclical lower abdominal pain of at least 6 months 
duration, which is unrelated to pregnancy and not due exclusively to dysmenorrhea or dyspareunia.”
Prevalence
•	 Prevalence ranges from 6.4 to 25.4% in different countries.
•	 Variation in prevalence is influenced by study design and case definitions.
•	 Most population-based studies determining prevalence have been limited to women in their reproductive 
years.
Individual & societal burden
•	 Poor quality of life.
•	 Psychosocial distress, marital problems and sexual dysfunction.
•	 Significant economic burden, including direct and indirect costs as well as loss of working time from paid 
work.
Etiology & risk factors
•	 Etiology and risk factors for CPP are not fully understood.
•	 CPP may be a manifestation of one or more disorders of various organ systems and also involves psychosocial 
conditions.
•	 More epidemiological studies are needed to identify etiological and risk factors for CPP.
Diagnosis & management
•	 Specific diagnosis made in only about half of CPP cases.
•	 Management is challenging and a multidisciplinary approach to the management of CPP is highly 
recommended, particularly when no particular cause is identified and when pain persists even after the 
underlying pathologies have been treated.
•	 Treatment should be directed at underlying cause of CPP if any is found.
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CPP is yet to be known. There may be a need for a 
tool to be developed and validated specifically for the 
identification of pelvic pain with neuropathic features 
in the near future. Such tool may become a useful 
 component of CPP evaluation.
The management of CPP can be particularly chal-
lenging for healthcare providers as well as patients. 
Unfortunately, many reviews of management strategies 
for CPP have shown that there is a paucity of evidence-
based options, making it more difficult for both parties 
to make informed decisions [89–91]. More clinical trials 
are necessary to evaluate medical, lifestyle and psycho-
logical interventions for CPP [90]. It would be impor-
tant for studies to evaluate the effectiveness of chronic 
pain management strategies which have been shown 
to be beneficial for other chronic pain syndromes but 
have not been extensively evaluated for the manage-
ment of CPP in women. For example, cognitive inter-
ventions and exercise used for several chronic pain con-
ditions including: fibromyalgia, chronic low back pain 
and other widespread/regional pain conditions [92,93]. 
In the meantime, multidisciplinary care for patients 
with CPP, especially where no known cause is identi-
fied, should be promoted.
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